STA
MRNA icon

Summit Trail Advisors’s Moderna MRNA Stock Holding History

Summit Trail Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$922K Sell
18,141
-8,082
-31% -$377K 0.01% 970
2025
Q4 		$773K Buy
26,223
+5,295
+25% +$144K 0.01% 937
2025
Q3 		$541K Buy
+20,928
New +$584K 0.01% 1057
2025
Q1 		– Sell
-7,281
Closed -$303K – 453
2024
Q4 		$303K Buy
7,281
+1,927
+36% +$92.1K 0.01% 288
2024
Q3 		$358K Buy
5,354
+1,796
+50% +$165K 0.01% 493
2024
Q2 		$423K Buy
3,558
+403
+13% +$51K 0.01% 410
2024
Q1 		$336K Buy
+3,155
New +$318K 0.01% 426
2023
Q4 		– Sell
-2,643
Closed -$273K – 584
2023
Q3 		$273K Buy
2,643
+501
+23% +$55.9K 0.01% 399
2023
Q2 		$260K Buy
2,142
+649
+43% +$86.6K 0.01% 405
2023
Q1 		$229K Buy
1,493
+195
+15% +$32.2K 0.01% 366
2022
Q4 		$233K Buy
+1,298
New +$212K 0.01% 334
2022
Q2 		– Sell
-1,274
Closed -$219K – 403
2022
Q1 		$219K Sell
1,274
-50
-4% -$8.42K 0.02% 291
2021
Q4 		$336K Buy
1,324
+138
+12% +$40.3K 0.02% 211
2021
Q3 		$456K Buy
+1,186
New +$437K 0.03% 169

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Summit Trail Advisors's MRNA Position: Q1 2026 in Review

Summit Trail Advisors reduced its Moderna (MRNA) stake by 31% in Q1 2026, selling an estimated $377K and leaving 18,141 shares worth $922K. The position accounts for 0.01% of the portfolio, ranked #970.

Summit Trail Advisors first reported a position in MRNA in Q3 2021 and has held it in 14 quarters since. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Summit Trail Advisors held 18,141 shares of Moderna worth $922K as of Q1 2026.
  • Summit Trail Advisors sold 8,082 Moderna shares in Q1 2026, an estimated $377K.
  • Moderna made up 0.01% of Summit Trail Advisors's portfolio in Q1 2026, its #970 holding.
  • Summit Trail Advisors first reported a position in Moderna in Q3 2021 and has held it in 14 quarters since.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.